MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Cassava Sciences, Inc. (NASDAQ: SAVA)*
Organization & Developments: Cassava Sciences
Parents
Cassava Sciences, Inc. (NASDAQ: SAVA)*
Children
2021: 5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market
2021: Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
2021: Cassava Sciences Can Get To Market Early In Alzheimer's
2021: Cassava Sciences: A Close Look
2021: Cassava Sciences: Welcome To The Casino
2021: Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs?
2021: Historic Day In Alzheimer's As Cassava Sciences' Simufilam Improves, Not Just Stabilizes, Cognition And Is Again Shown Safe
2021: More On Cassava Sciences' Controversy
2022: Cassava Sciences Drama Coming To A Head_ seekingalpha.com
2022: Cassava Sciences Looks As Good Of A Purchase As Ever
2022: Cassava Sciences Misses Out On The Alzheimer's Space Party_seekingalpha.com
2022: Cassava Sciences Stock: Huge Returns Or Catastrophic Losses_seekingalpha.com
2022: Cassava Sciences: 3 Key Factors Dictating Alzheimer Drug Developer's Fortunes In 2023_seekingalpha.com
2022: Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate_seekingalpha.com
2022: Cassava Sciences: Not Betting On This Moon Shot_ seekingalpha.com
2022: Cassava Sciences' Motion To Dismiss Securities Action Made Public - 3 Key Takeaways_ seekingalpha.com
2022: Cassava: High Risk Speculative Play With Enormous Potential_ seekingalpha.com
2023: Buy Cassava Sciences For Imminent Data Readout_seekingalpha.com
2023: Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
2023: Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet
2023: Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims (NASDAQ:SAVA)
2023: Cassava Sciences' Luck Hasn't Run Out Yet_ seekingalpha.com
2023: Cassava Sciences' Simufilam Mechanism Validated_ seekingalpha.com
2023: Cassava's Mixed Alzheimer's Data Underwhelms Investors (Updated)
2024: All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment
2024: Cassava Execs Step Down Amid DOJ Probe of Possible Alzheimer’s Drug Fraud
2024: Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
2024: Cassava Sciences Announces Completion of an Interim Safety
2024: Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure_ seekingalpha.com
2024: Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
2024: Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops
2024: Cassava Sciences: New CEO, Same Old Problems
2024: Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
2024: Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin_ seekingalpha.com
2024: Cassava Sciences: Pivotal Alzheimer's Data May Push Stock Toward Book Value
2024: Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
2024: Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
2024: The Steep Climb Ahead For Cassava Sciences' Alzheimer's Drug
2025: Cassava lays off 3rd of workforce in wake of phase 3 Alzheimer's fail
2025: Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments_seekingalpha.com
2025: Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value_
2025: Simufilam's Collapse Leaves Cassava Searching For A Viable Future
Jumps
*Key People: Cassava Sciences
Finance & Acquisitions: Cassava Sciences